Pharma & Life Sciences
March 22, 2021, 8:30 p.m.
Mitsubishi Chemical and J & J’s Janssen unit have won a decision confirming the validity of three patents for the diabetes drugs Invokana and Invokamet, a loss for the generic drug maker Zydus Cadila.
- “Zydus has not shown” that any person in the field “selected dapagliflozin as the lead compound” or was motivated to modify the link “to reach Canagliflozin,” wrote US District Judge Freda Wolfson in a statement released Monday in federal court in Trenton, New Jersey
- Wolfson rejected Zydus’ claim that the patents should not have been granted because they were too obvious
- Zydus had …
© 2021 The National Affairs Bureau, Inc.
All rights reserved